NEW YORK (Reuters Health) – A European study indicates that patients with T-cell prolymphocytic leukemia may respond well to induction chemotherapy using fludarabine, mitoxantrone and cyclophosphamide, followed by…
NEW YORK (Reuters Health) – Environmental factors appear to influence the incidence of papillary thyroid microcarcinomas (PTMCs), according to a comparison of epidemiologic data from Sicily and the…
NEW YORK (Reuters Health) – In a randomized controlled trial, the anti-CA-125 vaccine abagovomab did not prolong survival in patients with ovarian cancer in first remission — despite…
NEW YORK (Reuters Health) – Even without conventional conditioning and cytoxic chemotherapy, an allogeneic hematopoietic cell transplant (HCT) can have a substantial benefit in patients with advanced hematologic…
NEW YORK (Reuters Health) – Intraperitoneal chemotherapy may significantly improve long-term survival in ovarian cancer patients, a new study found. Data from 876 patients followed for a median…
Herbert Lepor, MD, and Danil V. Makarov, MD, MHS, discuss the case of a 58 year-old African American male with lower urinary tract symptoms in Part 1 of…
NEW YORK (Reuters Health) – Anticoagulant use may be a predictor of overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel, retrospective data suggest. The…
NEW YORK (Reuters Health) – Transplantation of hematopoietic cells from a donor with a single matched HLA haplotype, combined with post-transplant cyclophosphamide, may be a good alternative when…
NEW YORK (Reuters Health) – Symptomatic lymphoceles that develop after retroperitoneal lymph node dissection in gynecologic cancer patients can be dealt with safely and effectively by laparoscopic lymphocele…
NEW YORK (Reuters Health) – TNFerade biologic, a novel method of delivering tumor necrosis factor to tumor cells by gene transfer, does not prolong survival when added to…
